BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
Amneal is ramping up production of hydroxychloroquine sulfate at several of its manufacturing sites and expects to produce approximately 20 million tablets between now and mid-April. Those tablets will be made available nationwide through Amneal’s existing retail and wholesale customers, as well as through direct sales to larger institutions in need.
“This is a critical time in the fight against COVID-19,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “With our existing supply of hydroxychloroquine sulfate, and the ability to fast-track production, Amneal is well-positioned to help meet the potential demand for patients in need. We are grateful to our employees for working to accelerate production and will continue to do everything we can to support the healthcare needs of our communities.”
Hydroxychloroquine sulfate was first synthesized in 1946 and is in a class of medications historically used to treat and prevent malaria. Today, Amneal’s hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration (FDA) to treat malaria, rheumatoid arthritis, lupus, childhood arthritis and other autoimmune diseases. Hydroxychloroquine is not approved for the treatment of COVID-19; however, it has been identified as a possible treatment for COVID-19,1 and the U.S. government has requested its immediate availability.
Amneal has already begun shipping product. As a socially responsible company, Amneal will work to ensure its available inventory allocation is widely and evenly distributed to benefit the most patients possible.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has manufacturing operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal has an extensive portfolio of more than 225 marketed commercial products and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders. For more information, visit https://www.amneal.com.
Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995, as amended). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including, among other things, future operating results and financial performance, product development and launches, integration strategies and resulting cost reduction, market position and business strategy. Words such as “may,” “will,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “assume,” “continue,” and similar words are intended to identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. A list and descriptions of these risks, uncertainties and other factors can be found in the Company’s most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by any subsequently filed Quarterly Reports on Form 10-Q. Copies of these filings are available online at www.sec.gov, www.amneal.com or on request from the Company.
Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof, except as otherwise required by United States securities laws.
1 https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1
PP-PRS--US-0003
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20200320005551r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005551/en/
Tim Lynch / Jamie Moser
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
Source: Amneal Pharmaceuticals, Inc.
© Copyright Business Wire 2020
$AMRX
Recent AMRX News
- Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration • Business Wire • 09/05/2024 08:05:00 PM
- Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials • Business Wire • 08/20/2024 03:26:00 PM
- Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials • Business Wire • 08/20/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 07:12:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 03:04:22 PM
- UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More • IH Market News • 08/14/2024 09:56:35 AM
- Amneal Reports Second Quarter 2024 Financial Results • Business Wire • 08/09/2024 10:05:00 AM
- Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules • Business Wire • 08/07/2024 08:45:00 PM
- Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags • Business Wire • 07/29/2024 08:05:00 PM
- Amneal to Report Second Quarter 2024 Results on August 9, 2024 • Business Wire • 07/11/2024 08:05:00 PM
- Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant • Business Wire • 07/09/2024 08:05:00 PM
- Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab) • Business Wire • 07/01/2024 12:00:00 PM
- Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar • Business Wire • 07/01/2024 12:00:00 PM
- Amneal Releases 2023 Environmental, Social and Governance Report • Business Wire • 06/28/2024 12:00:00 PM
- Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies • Business Wire • 06/05/2024 12:00:00 PM
- Amneal to Participate at Upcoming Investor Conference • Business Wire • 05/22/2024 08:05:00 PM
- Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California • Business Wire • 05/22/2024 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 07:13:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:45:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:45:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:43:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:42:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:18:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 09:35:55 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM